315 related articles for article (PubMed ID: 32087187)
1. Introduction: Novel insights into TB research and drug discovery.
Grüber G
Prog Biophys Mol Biol; 2020 May; 152():2-5. PubMed ID: 32087187
[TBL] [Abstract][Full Text] [Related]
2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
3. Strategies to Combat Multi-Drug Resistance in Tuberculosis.
Singh V; Chibale K
Acc Chem Res; 2021 May; 54(10):2361-2376. PubMed ID: 33886255
[TBL] [Abstract][Full Text] [Related]
4. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
[TBL] [Abstract][Full Text] [Related]
8. Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
Xu Z; Gao C; Ren QC; Song XF; Feng LS; Lv ZS
Eur J Med Chem; 2017 Oct; 139():429-440. PubMed ID: 28818767
[TBL] [Abstract][Full Text] [Related]
9. Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches.
Kumar A; Karkara BB; Panda G
Chem Biol Drug Des; 2021 Nov; 98(5):787-827. PubMed ID: 34397161
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
[TBL] [Abstract][Full Text] [Related]
12. Key challenges in TB drug discovery: A perspective.
Shaik BB; Karpoormath R
Bioorg Med Chem Lett; 2024 Sep; 109():129846. PubMed ID: 38857850
[TBL] [Abstract][Full Text] [Related]
13. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and bioactivity of antitubercular peptides and peptidomimetics: an update.
De Leon Rodriguez LM; Kaur H; Brimble MA
Org Biomol Chem; 2016 Jan; 14(4):1177-87. PubMed ID: 26645944
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
Palomino JC; Martin A
Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
[TBL] [Abstract][Full Text] [Related]
17. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
Bhat ZS; Rather MA; Maqbool M; Ahmad Z
Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
[TBL] [Abstract][Full Text] [Related]
18. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
19. Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection.
Quan Y; Xiong L; Chen J; Zhang HY
J Biomol Struct Dyn; 2017 Feb; 35(3):616-621. PubMed ID: 26900080
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
